EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway

Yu Wang, Yuting Wang, Huabin Gao, Lin Chen, Shuai Zheng, Yongyu Chen, Huijuan Shi, Anjia Han

Cancer Treatment and Research Communications · 2025

DOI: 10.1016/j.ctarc.2025.100899 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Yu Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ezetimibe, Proprotein Convertase 9, MAP Kinase Signaling System. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To investigate the effect and molecular mechanism of ezetimibe on colorectal cancer (CRC), our study found that ezetimibe significantly inhibited the proliferation and progression of CRC. Further study showed that RPS6KA2 might be the target gene of ezetimibe treatment on CRC. RPS6KA2 expression was significantly lower in human CRC tissue samples and associated with T classification and vascular invasion of tumor cells. RPS6KA2 inhibited proliferation, migration, and invasion of CRC cells. The underlying mechanisms indicated that interaction between RPS6KA2 and PCSK9 was observed within the cytoplasmic compartment of CRC cells. RPS6KA2 suppressed PCSK9 and MAPK signaling pathway in CRC cells. BI-D1780 which is an inhibitor of RPS6KA2 increased PCSK9 and MAPK signaling pathway related proteins expression in SW620 cells. However, an inhibitor or stimulator of MAPK did not affect RPS6KA2 and PCSK9 expression, respectively. In vivo, CRC cells with RPS6KA2 or PCSK9 overexpression could inhibit or promote tumor growth and metastasis, respectively. PCSK9 promoted proliferation, migration, and invasion of CRC cells. PCSK9 expression was higher in human CRC samples and associated with N classification and TNM stage of CRC. In conclusion, our study firstly suggests that ezetimibe suppresses CRC progression by upregulating RPS6KA2 while downregulating PCSK9/MAPK signaling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsEzetimibeProprotein Convertase 9MAP Kinase Signaling SystemRibosomal Protein S6 Kinases, 90-kDaHumansCell ProliferationMiceMaleAnimalsFemaleCell Line, TumorCell MovementMiddle AgedAnticholesteremic AgentsXenograft Model Antitumor AssaysGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Colorectal cancerEzetimibeMAPKPCSK9RPS6KA2

Substanzen

EzetimibePCSK9 protein, humanProprotein Convertase 9Ribosomal Protein S6 Kinases, 90-kDaAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of Pathology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China.
  • Department of Pathology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China. Electronic address: shihj@mail.sysu.edu.cn.
  • Department of Pathology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China. Electronic address: hananjia@mail.sysu.edu.cn.

Förderung

  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Wang, Y., Wang, Y., Gao, H., Chen, L., Zheng, S., Chen, Y., Shi, H., & Han, A. (2025). Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100899

Vancouver

Wang Y, Wang Y, Gao H, Chen L, Zheng S, Chen Y, et al. Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100899

BibTeX
@article{Wang2025,
  author = {Wang, Yu and Wang, Yuting and Gao, Huabin and Chen, Lin and Zheng, Shuai and Chen, Yongyu and Shi, Huijuan and Han, Anjia},
  title = {Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway},
  journal = {Cancer Treatment and Research Communications},
  year = {2025},
  doi = {10.1016/j.ctarc.2025.100899}
}
Kostenlos starten →